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Functional outcomes for long-term survivors of acute liver failure (ALF) are not well characterized. The aim of this prospective
study was to determine health-related quality of life in long-term adult ALF survivors. Acute Liver Failure Study Group registry
participants completed the Centers for Disease Control and Prevention Health-Related Quality of Life 14 and Short Form 36
(SF-36) questionnaires at 1- and/or 2-year follow-up study visits. Responses were compared among ALF subgroups and to
those for available general US population controls. Among the 282 adult ALF patients, 125 had undergone liver transplantation
(LT), whereas 157, including 95 acetaminophen overdose (APAP) patients and 62 non-APAP patients, were spontaneous sur-
vivors (SSs). APAP SS patients reported significantly lower general health scores and more days of impaired mental and
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physical health, activity limitations due to poor health, pain, depression, and anxiety in comparison with the other groups
(P 0.001). There were no significant differences in coma grade or in the use of mechanical ventilation or intracranial pres-
sure monitoring among the patient groups during their ALF hospitalization, but APAP SSs had significantly higher rates of psy-
chiatric disease and substance abuse (P< 0.001). In comparison with the general US population, a greater proportion of the
combined SS patients reported fair or poor health and 14 days of impaired physical/mental health and activity limitations
due to poor health. In addition, a greater proportion of LT recipients reported 14 days of impaired physical/mental health.
Similar results were observed with the SF-36 across the 3 ALF subgroups and in comparison with population controls. In con-
clusion, long-term adult survivors of ALF reported significantly lower quality of life scores than US population controls. Further-
more, APAP SS patients reported the lowest quality of life scores, possibly because of higher rates of premorbid psychiatric
and substance abuse disorders. Liver Transpl 19:991-1000, 2013. VC 2013 AASLD.
Received January 8, 2013; accepted May 22, 2013.
Acute liver failure (ALF) is defined as the development of
severe liver dysfunction with associated coagulopathy
and encephalopathy in patients without a known under-
lying liver disease. Although only 2000 to 3000 patients
develop ALF in the United States each year, these
patients are critically ill and require significant support-
ive care measures such as mechanical ventilation, vaso-
pressors, and renal replacement therapy to achieve
short-term survival.1 Despite the high initial mortality
rate among patients with ALF, nearly 67% will ultimately
survive, with 29% of these patients undergoing emer-
gency liver transplantation (LT).2 The pathogenesis of
cerebral edema in ALF patients remains unclear but can
lead to severe global impairment, seizures, and even
uncal herniation and death in some patients.3-5 Pilot
studies have suggested that ALF patients with cerebral
edema may have impaired cognition and survival during
short-term follow-up.3-5 Whether ALF patients develop
any long-term sequelae after such a catastrophic illness
has not been well studied. In addition, there have been
no large multicenter studies evaluating the long-term
health-related quality of life (HRQOL) and functional
outcomes in adult ALF survivors.
The Acute Liver Failure Study Group (ALFSG) is a
consortium of 13 academic medical centers that has
been prospectively studying the causes and outcomes
of adult ALF patients in the United States since 1998.
Much of the initial data from the ALFSG has been
focused on short-term (ie, 3-week) outcomes such as
survival and the need for LT. However, a large propor-
tion of these patients have now been followed up to 2
years from illness onset to determine their long-term
clinical and functional outcomes. The aim of this
study was to determine differences in HRQOL during
long-term follow-up among spontaneous survivors
(SSs) and LT recipients. In addition, we set out to
determine whether the severity of illness at ALF pre-
sentation was associated with long-term HRQOL out-
comes. A secondary aim was to compare HRQOL
outcomes for long-term survivors of ALF to those for
age- and sex-matched US population controls.
PATIENTS AND METHODS
US ALFSG
The ALFSG is a consortium of 13 US academic referral
centers funded by the National Institute of Diabetes
and Digestive and Kidney Diseases to conduct an
ongoing, prospective, observational study of the etiol-
ogy, clinical features, and outcomes of adult patients
with ALF. Enrollment criteria include the presence of
coagulopathy defined as an international normalized
ratio1.5 and any level of hepatic encephalopathy
within 26 weeks of illness onset in a patient with no
known underlying liver disease. The current study pop-
ulation consisted of consecutive adult ALF patients
who were enrolled between January 1, 1998 and July
1, 2010 and completed a long-term follow-up visit.
Data Collection
Local institutional review board approval was obtained
at all participating sites, and written informed consent
was obtained from each patient’s durable power of
attorney or next of kin at the time of enrollment.
Detailed patient demographics, medical histories, clini-
cal features, and laboratory values were collected at
study enrollment. Serial laboratory and clinical param-
eters were prospectively recorded for up to 3 weeks
after enrollment. At the end of 3 weeks, short-term
outcomes were classified as spontaneous survival, LT,
or death. SSs and LT recipients were to be followed up
at 12 and 24 months by the site investigator. At the
long-term follow-up study visits, subjects were queried
about their current medication use, medical diagnoses,
and interval health history since their ALF admission.
In particular, subjects were queried about active sub-
stance abuse involving alcohol, prescription drugs, and
illicit drugs. In addition, information regarding patients
with active mood disorders or other psychiatric ill-
nesses who required treatment, intervention, or moni-
toring were also recorded. Before February 2010, data
forms were sent to the data coordinating center for
review and entry into a central database. From Febru-
ary 2010 onward, data were entered into a Web-based
study database by the study sites. Periodic site visits
were conducted by the ALFSG leadership to verify
source documents. A certificate of confidentiality was
obtained from the National Institutes of Mental Health
for the entire study.
Short Form 36 (SF-36) Questionnaire
The SF-36 (version 1.0) is a widely used quality of life
(QOL) instrument. The questionnaire comprises 8
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scales: Physical Functioning (PF), Social Functioning
(SF), Role–Physical (RP), Role–Emotional (RE), Mental
Health (MH), Vitality (VT), Bodily Pain (BP), and Gen-
eral Health (GH). Responses to questions in each scale
are combined to create a score ranging from 0 (low) to
100 (high). In addition, these individual scale scores
can be combined to create separate physical and
mental health summary scores. The SF-36 question-
naire was to be completed 12 and 24 months after the
onset of ALF. Population norms were obtained from
the SF-36 scoring manual, which includes 2474 indi-
viduals (with 47% between the ages of 18 and 44
years and 57% female). Population norms were
obtained only for the physical and health composite
scores.
Centers for Disease Control and Prevention
(CDC) Health-Related Quality of Life 14
(HRQOL-14)
The CDC Health-Related Quality of Life 14 (HRQOL-
14) is a 4-item Healthy Days Core Module designed to
assess the overall health of the general US population.
Since 1993, the CDC HRQOL-4 has been integrated
into the state-based Behavioral Risk Factor Surveil-
lance System. The CDC HRQOL-14 is a 14-item ques-
tionnaire that includes questions from the Health
Days Core Module as well as the Activity Limitations
Module and the Healthy Days Symptoms Module.6,7
Each 1-day change in any of the Healthy Days meas-
ures is considered clinically meaningful. As such, this
instrument allows direct comparisons of mean healthy
days among different patient groups, and the results
can be compared to those for the general US popula-
tion. The CDC HRQOL-14 questionnaire was com-
pleted by patients at the same study follow-up visit
used for the SF-36. Population norms were obtained
from Behavioral Risk Factor Surveillance System Web
site data collected between 2006 and 2010.8 The nor-
malized population consisted of 1,934,859 individu-
als, with 28% between the ages of 18 and 44 years
and 62% female. Population norms were aggregated
for 2006 to 2010 by sex or age group (18-24, 25-34,
35-44, 45-54, 55-64, 65-74, and 75 years).
Statistical Analysis
SAS 9.2 (SAS Institute, Inc., Cary, NC) was used to
perform statistical analysis. Baseline variables were
described with counts and percentages for categorical
data or with means and standard deviations (or
medians and interquartile ranges) for continuous nor-
mal (or skewed) data. For variables identified as clini-
cally relevant, statistical tests were performed with
chi-square, analysis of variance, or Kruskal-Wallis
tests. Survey items were reported as counts for the
CDC QOL questionnaire and as standardized means
and standard deviations for the SF-36 questionnaire.
Measures between groups were compared with a
global analysis of variance test or chi-square test fol-
lowed by all Tukey multiple-comparison, adjusted,
pairwise comparisons when there was significance.
For pairwise comparisons against population norms,
the Student t test or Wald test of proportions was
used.
RESULTS
Demographic Characteristics and Clinical
Parameters
From January 1, 1998 to July 1, 2010, there were
1850 adult ALF patients enrolled in the ALFSG.
Among the 1138 survivors 3 weeks after enrollment,
773 patients had at least 1 long-term follow-up study
visit completed via a clinic visit, telephone interview,
or chart review or had died beyond 21 days (Fig. 1).
There were 282 patients who completed at least 1
QOL survey at month 12 or 24. Among these patients,
277 completed the HRQOL-14 (76 completed it at
both visits), and 281 completed the SF-36 (79 com-
pleted it at both visits). The baseline characteristics of
the 282 study patients, including the need for life
support and initial illness severity, were generally
similar to those of the 405 excluded patients. How-
ever, the included patients were significantly older
and were more likely to have undergone LT, have a
higher body mass index, and be non-Hispanic in com-
parison with the excluded patients (see Supporting
Table 1).
In the study population, 125 patients had under-
gone LT, whereas 157 were SSs; the latter included
95 with an acetaminophen overdose (APAP) and 62
with non-APAP etiologies. The APAP SS group
included 58 subjects with an unintentional overdose,
28 subjects with an intentional overdose, and 9 sub-
jects with unknown intent. The etiology was missing
for 2 SS patients, and they were excluded from strati-
fied analyses. The most common underlying etiologies
for ALF among the LT recipients included drug-
induced liver injury (25%), indeterminate etiologies
(21%), and autoimmune hepatitis (18%); among the
non-APAP SSs, the most common etiologies of ALF
included drug-induced liver injury (26%), hepatic
ischemia (13%), and hepatitis A (13%). Thirteen of the
LT recipients (10.7%) had developed ALF because of
APAP. No significant differences were noted in patient
demographics, including age, sex, race/ethnicity,
employment status, years of education, and marital
status (Table 1). The APAP SSs demonstrated signifi-
cantly higher rates of substance abuse and underly-
ing psychiatric disease in comparison with the LT
recipients and non-APAP SSs (Table 1). However, the
58 unintentional APAP SSs were significantly less
likely to have a psychiatric comorbidity than the
intentional APAP patients (48% versus 82%,
P50.003), but the proportions with a history of sub-
stance abuse were similar (47% versus 43%,
P50.75).
The LT recipients had significantly higher baseline
serum total bilirubin levels and international normal-
ized ratios than the SSs. The APAP SSs exhibited
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significantly higher aspartate aminotransferase and
alanine aminotransferase levels in comparison with
the LT and non-APAP SS groups. However, there were
no significant differences in the baseline serum creati-
nine levels between the patient groups or in the rates
of mechanical ventilation, renal replacement therapy,
or intracranial pressure monitoring during their
admission for ALF. The percentages of patients with a
stage 3 or 4 coma grade were also similar among the
LT recipients and the SS groups.
CDC HRQOL-14 Results
ALFSG Adult Cohort
The CDC HRQOL-14 form was completed by 277 ALF
patients at a median of 708 days after enrollment
(range5127-3645 days). Within the Healthy Days
Core Module, APAP SSs were more likely than non-
APAP SSs and LT recipients to report fair or poor gen-
eral health (34% versus 30% and 14%, P50.001; see
Supporting Table 2). These patients also reported
more days of impaired physical health (9.5 versus 5.6
and 6.2, P50.012), impaired mental health (11.2 ver-
sus 5.7 and 6.7, P50.001), and activity limitations
due to poor physical or mental health (9.1 versus 4.9
and 4.5, P<0.001).
Within the Healthy Days Symptoms Module, APAP
SSs reported, in comparison with non-APAP SSs and
LT recipients, more days of pain (10.8 versus 4.8 and
4.9, P<0.001), depression (11.2 versus 5.3 and 5.7,
P<0.001), and anxiety (12.7 versus 4.8 and 6.7,
P<0.001). No significant differences were noted
between the groups with respect to days of inadequate
sleep or days of poor energy. Additionally, patients in
these groups showed no significant differences in
their responses to questions within the Activity Limi-
tations Module. Among the 76 ALF patients who
Figure 1. Flowchart for patients.
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completed the survey at both 12 and 24 months,
there were no significant changes in the number of
unhealthy days for the 41 SS patients during follow-
up or for the 35 LT recipients during follow-up (data
not shown).
ALFSG Versus Population Controls
In comparison with the general US population, a
higher proportion of SSs (APAP and non-APAP SSs
combined) reported fair or poor general health (32%
versus 16%, P<0.001; Figs. 2 and 3 and Supporting
Table 4). This finding was confined primarily to
women and patients who were 25 to 54 years old.
Transplant recipients reported a general health status
similar to that of the general US population. Higher
percentages of both SSs and LT recipients reported
>14 days per month of poor physical health in com-
parison with the general US population [28% versus
11% (P<0.001) and 20% versus 11% (P0.001)], with
TABLE 1. Baseline Characteristics of the Adult ALFSG Patient Population
Patients
(n)
Non-APAP
SSs (n562)
APAP
SSs (n595)
LT Recipients
(n5125) P Value
Age (years)* 282 42.5614.2 38.2613.2 40.4613.0 0.52
Female (%) 282 71.0 74.7 64.8 0.27
Race (%) 282 0.17†
White 79.0 86.3 73.6
Black 14.5 7.4 18.4
Other 6.5 6.3 8.0
Ethnicity: non-Hispanic (%) 282 96.8 97.9 92.0 0.13†
Full/part-time employment (%) 216 64.0 63.6 72.0 0.44
Education (years)* 181 13.862.0 12.462.2 13.362.7 0.56
Marital status: married/significant other (%) 250 56.1 39.1 52.8 0.07
Etiology (%) 282 —‡
APAP 0 100 10.7
Drug-induced liver injury 25.8 0 24.6
Autoimmune hepatitis 11.3 0 18.0
Hepatitis A 12.9 0 1.6
Hepatitis B 6.5 0 13.1
Ischemia 12.9 0 0
Indeterminate 11.3 0 21.3
Other§ 19.4 0 10.7
Medical history
Body mass index (kg/m2)* 231 28.866.8 26.467.0 28.866.5 0.62
Psychiatric disease (%) 282 37.1 57.9 18.4 <0.001
Substance abuse (%) 282 9.7 48.4 11.2 <0.001
Intravenous drug user history (%) 278 3.3 6.4 2.4 0.32†
Hypertension (%) 282 24.2 13.7 13.6 0.13
Endocrine/diabetes (%) 282 30.7 11.6 14.4 0.005
Presenting features and clinical complications
Time from jaundice to ALF (days)†† 235 5.0 (2.0) 1.0 (2.0) 10.5 (17.3) <0.001
International normalized ratio†† 279 1.9 (1.7) 2.5 (1.7) 3.0 (1.8) <0.001
Alanine aminotransferase (IU/L)†† 279 1659 (3769) 3195 (3769) 711 (1776) <0.001
Aspartate aminotransferase (IU/L)†† 281 948 (6514) 2600 (6514) 622 (1511) <0.001
Bilirubin (mg/dL)†† 281 10.5 (3.2) 4.2 (3.2) 21.5 (15.7) <0.001
Creatinine (mg/dL)†† 282 1.3 (2.8) 1.4 (2.8) 1.1 (1.4) 0.30
Admission grade 3=4 encephalopathy (%) 280 36.1 40.0 34.7 0.71
Peak grade 3/4 encephalopathy (%) 282 43.6 47.4 55.2 0.27
Model for End-Stage Liver Disease score* 278 13.664.7 11.466.8 15.965.1 0.001
Intubation (%) 281 30.7 41.1 30.7 0.22
Continuous venovenous hemofiltration
or dialysis (%)
112 31.8 51.4 36.4 0.25
Intracranial pressure monitoring (%) 271 6.6 5.4 11.0 0.36†
Any infection (%) 282 38.7 40.0 37.6 0.94
*The data are presented as means and standard deviations.
†Fisher’s exact test.
‡The P value is not provided because the definition of strata implies a different distribution.
§Other includes pregnancy, Budd-Chiari syndrome, hepatitis C, hepatitis E, mushrooms, Wilson’s disease, and
miscellaneous.
††The data are presented as medians and interquartile ranges; a nonparametric equivalent test (Kruskal-Wallis) was used.
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significant differences noted in SS patients of both
sexes, female LT patients, SS patients under the age
of 55 years, and LT patients between the ages of 18
and 44 years. Greater proportions of both SSs and LT
recipients reported 14 days per month of poor men-
tal health in comparison with the general US
population [31% versus 10% (P0.001) and 20% ver-
sus 10% (P<0.001)]. Among SSs, this finding was
observed in both men and women between the ages of
25 and 54 years, but it was limited to women and
patients between the ages of 18 and 24 years among
transplant recipients. Both SSs and transplant
Figure 2. Results for CDC HRQOL Healthy Days Core Module questions from 156 SSs (41 males and 115 females) and 123 LT recipi-
ents (43 males and 80 females) stratified by sex. Overall, female SSs had significantly poorer HRQOL indices than the general popula-
tion, whereas the scores for male SSs were significantly different only in days of activity limitations. The scores for male and female LT
recipients were similar to those for the general US population. *P0.001 versus the general US population.
Figure 3. Results for CDC HRQOL Healthy Days Core Module questions from 148 SSs (n529 for 18-24 years, n537 for 25-34 years,
n536 for 35-44 years, n527 for 45-54 years, and n519 for 55-64 years) and 119 LT recipients (n514 for 18-24 years, n526 for
25-34 years, n531 for 35-44 years, n530 for 45-54 years, and n518 for 55-64 years) stratified by age. The HRQOL scores were sig-
nificantly lower for the SS patients in most age groupings, whereas the scores for the LT recipients were generally similar to those for
age-matched population controls. *P0.001 in comparison with the general US population.
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recipients were more likely to report 14 days per
month of activity limitations due to poor physical or
mental health [28% versus 7% (P0.001) and 12%
versus 7% (P50.02)]. Among SSs, this finding was
confined to patients between the ages of 25 and 64
years; there were no differences in the LT population.
SF-36 Results
ALFSG Adult Cohort
The SF-36 questionnaire was completed by 281 ALF
patients at a median of 706 days after enrollment
(interquartile range5448-859 days), and they
included 95 APAP SSs, 62 non-APAP SSs, and 124 LT
recipients. The demographic data were similar to
those for the patient population completing the CDC
HRQOL-14 questionnaire, and there were no signifi-
cant differences between the 3 subgroups. In compar-
ison with non-APAP SSs and LT recipients, APAP SSs
reported lower scale scores for BP (56 versus 70 and
71, P<0.001), GH (53 versus 59 and 63, P50.024),
VT (43 versus 53 and 55, P50.003), SF (61 versus 75
and 76, P<0.001), RE (57 versus 78 and 70,
P50.006), and MH (62 versus 75 and 74, P<0.001;
Fig. 4A and Supporting Table 3). There were no signif-
icant differences in the scores between the 3 groups
for the PF, RP, or physical health summary scales;
however, the mental health summary scores were sig-
nificantly lower for the APAP SS group versus the
other patient groups (Fig. 4B). There were no signifi-
cant differences in the mental or physical health sum-
mary scores over time for the 37 SSs or the 32 LT
recipients with paired data (data not shown).
ALFSG Versus Population Controls
Sex-adjusted physical and mental health summary
scale scores were significantly lower for the APAP SS
group and for some of the other subgroups in com-
parison with US population norms (Fig. 4B).
DISCUSSION
This is the first large, prospective, multicenter study
to assess QOL outcomes in long-term adult survivors
Figure 4. (A) SF-36 scores for 95 APAP SSs, 62 non-APAP SSs, and 124 LT recipients. The SF-36 domains are PF, RP, BP, GH, VT,
SF, RE, and MH. (B) SF-36 component scores: PCS and MCS. *There was statistical significance at p0.001 in comparison with the
general US population. ¶There was overall statistical significance at p0.001 for a comparison of non-APAP SSs, APAP SSs, and LT
recipients.
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of ALF. The results of this study demonstrate that
ALF SSs reported significantly more days of poor
physical and mental health during long-term follow-
up in comparison with the general US population.
Among the ALF patient subgroups, APAP SSs were
significantly more likely to report impairment than
non-APAP SSs and LT recipients. Similar findings
were noted with both the CDC HRQOL-14 and SF-36
questionnaires (Figs. 2–4).
Prior retrospective studies of HRQOL in ALF
patients have focused primarily on patients who have
undergone LT. During follow-up, ALF LT recipients
have reported QOL scores similar to those of patients
with cirrhosis undergoing LT.9 In addition, no signifi-
cant differences in QOL have been noted between
APAP and non-APAP ALF transplant recipients.10
However, ALF patients experience higher rates of
depression, anxiety, and posttraumatic stress disor-
der after LT in comparison with LT recipients with cir-
rhosis, and this finding correlates with the higher rate
of poor mental health among LT recipients observed
in our study.11 This observation may be due to the
fact that ALF patients are previously healthy, gener-
ally young individuals who have suffered a sudden
life-threatening illness, whereas most LT recipients
with cirrhosis have been ill for several years and may
have developed better coping skills. Furthermore,
prior studies have shown that ALF LT recipients are
less likely to resume employment than LT recipients
with cirrhosis, despite their younger age.9
The SF-36 questionnaire has been used to assess
HRQOL and functional outcomes in patients with
other chronic diseases and in subjects who have expe-
rienced severe acute illness. In particular, the SF-36
has been administered to patients with various liver
diseases, including chronic hepatitis C and primary
biliary cirrhosis.12-14 The SF-36 has also specifically
been evaluated in LT recipients, and individual
domain scores from the current study are similar to
prior data reported 24 months after LT in patients
with cirrhosis.15 Although LT recipients with cirrhosis
often report significantly improved QOL in the early
posttransplant period in comparison with their pre-
transplant status, posttransplant QOL usually
remains lower than that of age-matched population
controls.16,17 The durability of improved QOL after LT
is also uncertain, with several studies suggesting that
patients’ psychological well-being may begin to erode
as early as 1 year after LT.18,19 In addition, episodes
of rejection, osteoporosis, and recurrent disease are
associated with further declines in QOL scores during
long-term follow-up in LT recipients with cirrhosis.20-
22 However, the QOL scores of LT recipients remain
better than those reported for patients with congestive
heart failure.23 Although the underlying etiology of
cirrhosis affects HRQOL in the pretransplant period,
no significant differences in QOL based on the etiol-
ogy of cirrhosis have been noted 6 months after LT,
but more recent studies suggest that patients with
chronic HCV may have poorer HRQOL during long-
term follow-up.22,24
Impaired QOL during long-term follow-up, as meas-
ured by the SF-36, has also been seen in previously
healthy patients who have suffered from a severe
acute illness such as acute renal failure, necrotizing
pancreatitis, subarachnoid hemorrhaging, or acute
respiratory distress syndrome.25-28 A stay in the
intensive care unit with associated vital organ dys-
function may be associated with reduced QOL,
although this finding could also be attributable to pre-
existing disease.29 Notably, we did not find a signifi-
cant relationship between markers of disease severity
(eg, the need for intubation or dialysis or the ence-
phalopathy grade) and SF-36 or HRQOL-14 scores
during long-term follow-up.
The CDC HRQOL-14 is a more recently developed
instrument designed to assess the HRQOL of the gen-
eral US population. The 4-item Healthy Days Core
Module has been used to assess long-term QOL in
patients with several chronic diseases, including
osteoarthritis, rheumatoid arthritis, coronary artery
disease, and diabetes mellitus.30-32 Studies using the
CDC HRQOL-4 have shown that survivors of severe,
life-threatening diseases such as cerebrovascular
accidents and breast cancer report more unhealthy
days per month than the general US population. In
addition, a study of older adults indicated that
patients with lower CDC HRQOL-4 scores had higher
rates of hospitalization and death during follow-up.33
A key advantage of the CDC HRQOL-14 is its ability
to quantify QOL impairment in terms of unhealthy
days and further make direct comparisons with the
general population. In our study, APAP SSs reported
nearly twice as many days per month of impaired
physical and mental health, activity limitation, pain,
depression, and anxiety in comparison with the other
groups (Fig. 2), and this indicated that they had the
poorest functional status during follow-up.
Our findings of increased days of pain, depression,
and anxiety for APAP SSs is consistent with prior data
regarding the increased incidence of chronic pain and
underlying psychiatric disease in this patient popula-
tion.34 As such, it is difficult to determine to what
extent the long-term QOL impairment observed in
this study is attributable to the ALF episode itself ver-
sus preexisting medical or psychiatric factors because
baseline QOL scores were not available for these
patients. Our findings also demonstrate that non-
APAP SSs may experience substantial physical and
mental health impairment during follow-up despite
normalization of hepatic laboratory abnormalities.
Among ALF LT recipients, impaired mental and physi-
cal QOL domains have been reported primarily for
women and younger patients. As such, a significant
subset of ALF survivors may benefit from targeted
interventions, including counseling, psychiatric care,
and physical therapy.
Because of the low incidence of ALF and the limited
study population size, we were unable to identify pre-
senting laboratory or clinical parameters that corre-
lated with long-term QOL scores. However, there were
no significant differences in the baseline coma grade
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or need for intracranial pressure monitoring among
APAP SSs, non-APAP SSs, and LT recipients.
Although prior studies have suggested that adherence
to follow-up and immunosuppression compliance may
be lower among APAP LT recipients, we were not able
to compare QOL outcomes for APAP LT recipients ver-
sus non-APAP LT recipients because of the small
number of patients.35
There were 405 ALFSG patients who did not com-
plete the HRQOL forms and were, therefore, excluded
from this analysis (Supporting Table 1). Overall, the
included patients were older, more likely to be non-
Hispanic and have undergone LT, and less likely to
have had APAP. Therefore, the QOL scores of the
included ALFSG patients may intrinsically have been
better in comparison with those who did not complete
the surveys because the LT recipients had better QOL
scores. The higher proportion of LT recipients cap-
tured in the current study group likely is related to
the fact that LT recipients return more frequently for
concurrent care than those who have recovered. In
light of these limitations, confirmation of our findings
in other large, independent cohorts of ALF patients is
needed. Nonetheless, the current study represents the
largest study of QOL outcomes in ALF patients com-
pleted to date. In addition, the prospective enrollment
of patients from multiple sites and the administration
of widely used and validated QOL instruments at pre-
determined study visits have helped to improve the
generalizability and importance of our findings.
In conclusion, our study demonstrates that long-
term adult survivors of ALF exhibit diminished QOL
in comparison with age- and sex-matched population
controls. Furthermore, APAP SSs reported decreased
QOL across several domains in comparison with non-
APAP SSs and LT recipients. These results were some-
what surprising because LT recipients are known to
have more frequent and severe cerebral edema and
require long-term use of potentially neurotoxic immu-
nosuppressive agents.36,37 We speculate that the
observed differences in long-term HRQOL outcomes
among the ALF patient groups may have been the
result of other preexisting medical and psychiatric
comorbidities rather than the patients’ initial ALF ill-
ness and hospital course. Ongoing studies of neuro-
psychological function by our group and others will
help us to better define the types and severity of
potential cognitive impairments that many long-term
ALF survivors report to their physicians.
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